Summary of Significant Accounting Policies (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2024

Dec. 31, 2023

Summary of Significant Accounting Policies

Schedule of carrying value of convertible debt

A roll forward of the carrying value of the convertible debt to March 31, 2024 is as follows:

	Balance		Conversion		Adjustment to		Balance
	December 31, 2023		January 3, 2024		fair value		March 31, 2024
Convertible debt at fair value	$	3,260,934	$	(99,416)	$	(165,382)	$	2,996,136

	Balance				Adjustment to		Balance
	December 31, 2022		Issued		fair value		December 31, 2023
Convertible debt at fair value	$	—	$	3,304,000	$	(43,066)	$	3,260,934

Schedule of United Kingdom research and development incentives receivable

	Current		Long-Term		Total
Balance at December 31, 2022	$	104,198	$	24,114	$	128,312
UK research and development incentives, transfer		24,114		(24,114)		—
UK research and development incentives		—		24,897		24,897
Adjustments to 2021 and 2022 incentives earned		(1,113)		—		(1,113)
UK research and development incentives cash receipt		(104,422)		—		(104,422)
Foreign currency translation		1,117		571		1,688
Balance at December 31, 2023	$	23,894	$	25,468	$	49,362

Schedule of potentially dilutive adjustments to the weighted average number of common shares excluded from the calculation

	As of March 31,
	2024	2023
Common stock purchase warrants	408,640	—
Stock options	56,568	11,946
Convertible debt	335,716	105,746
Total	800,924	117,692

	December 31,	December 31,
	2023	2022
Common stock purchase warrants	408,640	42
Stock options	56,609	11,946
Convertible debt	273,973	30,865
Total	739,222	42,853